Abbott's Similac Recall Triggers Overflow Demand For Answers
This article was originally published in The Tan Sheet
Consumer response to Abbott Laboratories' recall of powder Similac and other infant formula products initially exceeded the firm's capabilities to handle telephone calls and support online traffic to its websites
You may also be interested in...
Abbott Laboratories’ nutrition business – one of four divisions in the remaining diversified medical products firm – gains importance with the firm’s plan to spin off its research-based branded pharmaceuticals business.
Private label giant Perrigo is readying generic competitors to Reckitt Benckiser’s Mucinex and Takeda Pharmaceuticals’ Prevacid, CEO Joseph Papa says.
Abbott Laboratories executives say its nutritionals business is staying put and can succeed without mergers and acquisitions, despite dragging U.S. sales.